CB2 Selective Ligand Design via Segmentation and Local Quality
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current efforts to develop CB2 selective ligands for therapeutic use are hindered by a lack of information about the three-dimensional structures of CB receptors and ligand binding sites, leading to limited design of compounds that avoid psychotropic side effects.
Innovation Solution
Development of compounds with specific chemical scaffolds that selectively bind to CB2 receptors, such as those represented by Formula I and Formula II, which are used to create pharmaceutical formulations for targeting CB2 receptors and determining their 3D structure, enabling the design of novel CB2 selective ligands with potential therapeutic applications without psychotropic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CB1 receptor agonists are used to treat pain, then analgesic effects are achieved, but sedation and psychotropic effects occur
Solution Approach 1:
The patent segments the cannabinoid receptor system into two distinct subtypes (CB1 and CB2) with different functional profiles. By targeting CB2 receptors specifically, the invention achieves pain relief while avoiding the psychotropic side effects associated with CB1 activation, thus resolving the contradiction between effective pain treatment and harmful sedation/psychotropic effects
Solution Approach 2:
The invention applies local quality by designing ligands with specific chemical structures (Formula I and Formula II) that are selectively recognized by CB2 receptors. The compounds exhibit high affinity for CB2 while showing minimal activity at CB1 receptors, creating a localized therapeutic effect that addresses pain without producing unwanted central nervous system effects
2Adaptability or versatility
If CB2 selective ligands are designed without 3D structure information, then compound design is limited, but developing accurate 3D structure data requires complex experimental procedures
Solution Approach 1:
The patent employs computational modeling and molecular docking techniques to create virtual copies of the CB2 receptor structure and binding site. These computational models enable the design of selective ligands without requiring complex experimental structural biology procedures, thus resolving the contradiction between ligand design versatility and structural analysis complexity
Solution Approach 2:
The invention utilizes changes in chemical parameters (molecular weight, functional groups, steric properties) to optimize ligand binding affinity and selectivity for CB2 receptors. By systematically varying these parameters in the compound designs (Formulas I and II), the patent achieves high CB2 specificity without requiring complex 3D structural data
Data Source
AI summary
A compound of Formula I: (I) has activity as a cannabinoid receptor antagonist. In Formula 1, R1 is unsubstituted or substituted aryl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aralkyl, or unsubstituted or substituted heteroaryl; R2 is unsubstituted or substituted alkyl, unsubstituted or substituted aryl, or unsubstituted or substituted heteroaryl; and R3 is unsubstituted or substituted alkyl, unsubstituted or substituted aralkyl, or unsubstituted or substituted heteroaralkyl; with the proviso that at least one of Ri and R3 is other than unsubstituted aralkyl or R2 is other than unsubstituted aryl.